Modality
ADC
MOA
WRNi
Target
PRMT5
Pathway
JAK/STAT
MigraineADPKD
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
Jul 2022
→ Jan 2028
Phase 2Current
NCT04210107
1,679 pts·ADPKD
2022-07→2028-01·Not yet recruiting
1,679 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-131.8y awayPh2 Data· ADPKD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2
Not yet…
Catalysts
Ph2 Data
2028-01-13 · 1.8y away
ADPKD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04210107 | Phase 2 | ADPKD | Not yet recr... | 1679 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-2752 | Amgen | Preclinical | MDM2 |